Real-world data on over 4,000 patients using the medtronic minimed™ 780g system demonstrate time in range mirroring pivotal trial

Results demonstrate 76% time in range and 94% time in advanced hybrid closed loop mode dublin, june 2, 2021 /prnewswire/ -- medtronic plc (nyse:mdt), the global leader in medical technology, today announced real-world clinical outcomes for 4,120 individuals on the minimed™ 780g system, a small subset of those on the latest system today across nine countries in europe. data showed an average overall time in range of 76.2% and an overnight time in range of 83%, mirroring results from the pivotal trial.
MDT Ratings Summary
MDT Quant Ranking